- BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
- BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
- BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
- BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
- BeiGene Reports First Quarter 2024 Financial Results and Business Updates
- BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
More ▼
Key statistics
On Tuesday, Beigene Ltd (6160:HKG) closed at 87.80, 16.37% above the 52 week low of 75.45 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 86.30 |
---|---|
High | 87.80 |
Low | 85.75 |
Bid | 88.15 |
Offer | 88.15 |
Previous close | 85.80 |
Average volume | 1.04m |
---|---|
Shares outstanding | 1.38bn |
Free float | 1.31bn |
P/E (TTM) | -- |
Market cap | 122.13bn HKD |
EPS (TTM) | -4.55 HKD |
Data delayed at least 15 minutes, as of Jul 09 2024 08:59 BST.
More ▼